CELLemedy Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $8.93M

  • Investors
  • 6

CELLemedy General Information

Description

Developer of cancer immunotherapy designed to provide a cure through smart nano-medicine. The company offers cancer cell-related therapeutics, and immuno-oncology drugs through research and development, enabling doctors to improve the health of patients suffering from cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 4301, Healthcare Innovation Park
  • 172 Dolma-ro, Bundang-gu
  • Seongnam, Gyeonggi
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Room 4301, Healthcare Innovation Park
  • 172 Dolma-ro, Bundang-gu
  • Seongnam, Gyeonggi
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CELLemedy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 20-Sep-2023 $8.93M Completed Pre-Clinical Trials
1. Seed Round 01-Dec-2020 Completed Pre-Clinical Trials
To view CELLemedy’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

CELLemedy Patents

CELLemedy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240374744-A1 Protein and pharmaceutical composition comprising same for prevention or treatment of cancer Pending 17-Sep-2021
EP-4403567-A1 Novel protein and pharmaceutical composition comprising same for prevention or treatment of cancer Pending 17-Sep-2021
CA-3232442-A1 Novel protein and pharmaceutical composition comprising same for prevention or treatment of cancer Pending 17-Sep-2021
AU-2022346534-A1 Novel protein and pharmaceutical composition comprising same for prevention or treatment of cancer Pending 17-Sep-2021
EP-4335450-A1 Pharmaceutical composition for prevention or treatment of lung cancer Pending 03-May-2021 A61K38/1709
To view CELLemedy’s complete patent history, request access »

CELLemedy Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CELLemedy Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
CKD Venture Capital Corporate Venture Capital Minority
IBC Capital (Seoul) Venture Capital Minority
Stonebridge Ventures (Seoul) Corporate Venture Capital Minority
DAYLI Partners Venture Capital Minority
IMM Investment Asset Manager Minority
You’re viewing 5 of 6 investors. Get the full list »

CELLemedy FAQs

  • When was CELLemedy founded?

    CELLemedy was founded in 2016.

  • Where is CELLemedy headquartered?

    CELLemedy is headquartered in Seongnam, South Korea.

  • What is the size of CELLemedy?

    CELLemedy has 7 total employees.

  • What industry is CELLemedy in?

    CELLemedy’s primary industry is Biotechnology.

  • Is CELLemedy a private or public company?

    CELLemedy is a Private company.

  • What is CELLemedy’s current revenue?

    The current revenue for CELLemedy is .

  • How much funding has CELLemedy raised over time?

    CELLemedy has raised $12.5M.

  • Who are CELLemedy’s investors?

    CKD Venture Capital, IBC Capital (Seoul), Stonebridge Ventures (Seoul), DAYLI Partners, and IMM Investment are 5 of 6 investors who have invested in CELLemedy.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »